Acute Bacterial Skin and Skin Structure Infections Global Market Report 2024

The acute bacterial skin and skin structure infections market size has grown rapidly in recent years. It will grow from $10.57 billion in 2023 to $11.75 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth observed in the historical period can be credited to innovation in the healthcare industry, economic influences, trends in patient populations, advancements in diagnostic methods, and innovation in clinical trials.

The acute bacterial skin and skin structure infections market size is expected to see strong growth in the next few years. It will grow to $17.17 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The increase projected during the forecast period can be ascribed to global epidemiological factors, the introduction of new therapies into the market, swift diagnostic tool development, a patient-centric approach, and changes in treatment guidelines. Prominent trends anticipated in the forecast period involve the demographic composition of the patient population, concerns about antibiotic resistance, progress in treatment approaches, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA), and an emphasis on outpatient treatment.

The anticipated surge in the prevalence of skin infections is poised to drive the growth of the market for acute bacterial skin and skin structure infections in the future. Skin infections involve the invasion and proliferation of microorganisms such as bacteria, fungi, or viruses within the skin, resulting in various symptoms and discomfort. The increasing incidence of skin infections creates a heightened demand for therapeutic solutions, antibiotics, and innovative treatments to address acute bacterial and skin structure infections, ensuring that patients have access to optimal care and outcomes. For example, the UK Health Security Agency (UKHSA) reported in September 2022 that the percentage of Methicillin-resistant Staphylococcus aureus (MRSA) cases caused by skin and soft tissue infections had risen to 33.7% in 2022 from the previous year. Additionally, MRSA cases increased by 25.7% in the financial year spanning April 2020 to March 2021. Consequently, the escalating prevalence of skin infections is expected to propel the growth of the acute bacterial skin and skin structure infections market.

The increasing prevalence of chronic diseases is also anticipated to boost the growth of the acute bacterial skin and skin structure infections market in the coming years. Chronic diseases are characterized by long-term medical conditions that progress slowly and persist over an extended period, often lasting for years or a lifetime. The growth of chronic diseases contributes to the acute bacterial skin and skin structure infections market by heightening the risk of bacterial skin infections, necessitating increased treatments, hospitalizations, specialized care, research, public awareness, healthcare spending, and tailored interventions for affected individuals. As an illustration, the World Health Organization reported in September 2022 that 74% of the 41 million global deaths caused by non-communicable diseases (NCDs) or chronic diseases annually. The deaths included 17.9 million from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. Hence, the increasing prevalence of chronic diseases is a driving force behind the growth of the acute bacterial skin and skin structure infections market.

The high cost of treatment is anticipated to impede the market's growth in the future. The term 'high cost of treatment' refers to significant financial expenses associated with medical care, procedures, therapies, or interventions. Acute Bacterial Skin and Skin Structure Infections (ABSSSI) can be significantly affected by the high cost of treatment, impacting both individual patients and the healthcare system as a whole. For instance, the Centers for Disease Control and Prevention reported in August 2023 that 6.1% of adults aged 18 and over failed to obtain needed medical care due to cost in 2022. Therefore, the high cost of treatment poses a hindrance to the growth of the acute bacterial skin and skin structure infections market.

Major companies operating in the acute bacterial skin and skin structure infections market are strategically focusing on developing innovative single-dose therapies, such as Dalbonova, to gain a competitive edge. Dalbonova is a single-dose therapy designed for convenience and effectiveness, allowing patients to achieve desired results with a potent 1500 mg dose administered once. For example, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company, launched Dalbonova injection, a single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI). This injection reduces the risk of hospital-acquired diseases by offering a single-dose treatment and eliminating the need for hospital admissions. It is designed to treat ABSSSI caused by certain gram-positive microorganisms in patients of all ages, including newborns.

In April 2021, Endo International PLC, an Ireland-based generics and branded pharmaceutical company, entered into a partnership with Advanz Pharma Corp. Under this collaboration, Endo Ventures Limited is responsible for distribution, sales, marketing, medical affairs, and pricing, while Advanz Pharma is responsible for supplying Xydalba. Xydalba is indicated for treating acute bacterial skin and skin structure infections (ABSSSI) in adults and pediatric patients aged three months and older. Advanz Pharma Corp., a UK-based pharmaceutical company, provides treatment for acute bacterial skin and skin structure infections.

Major companies operating in the acute bacterial skin and skin structure infections market report are Pfizer Inc., AbbVie Inc., Novartis AG, Abbott Laboratories, Fresenius SE & Co. KGaA, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Menarini Group, Dr. Reddy's Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Zydus Lifesciences Limited, Eurofarma Laboratórios S.A., Glenmark Pharmaceuticals Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Alkem Laboratories Limited, Zhejiang Huahai Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd., Aurobindo Pharma Limited, Zhejiang Jingxin Pharmaceutical Co. Ltd., ACS Dobfar SpA, Melinta Therapeutics LLC, Shandong Luoxin Pharmaceutical Group Co. Ltd., Wakunaga Pharmaceutical Co. Ltd., Flynn Pharma Ltd.

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the acute bacterial skin and skin structure infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute bacterial skin and skin structure infections market consists of revenues earned by entities by providing services such as diagnostic testing, surgical procedures for abscess drainage or debridement, inpatient and outpatient healthcare services, and home healthcare and wound care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute bacterial skin and skin structure infections market also includes sales of wound dressings and bandages, medical devices for wound care, vaccines, hydrogen peroxide, and fusidic acid. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary classifications of acute bacterial skin and skin structure infections encompass hospital-acquired ABSSSIs and community-acquired ABSSSIs. Hospital-acquired ABSSSIs manifest as infections of the skin and underlying tissues that develop due to medical care or hospital stays. Active ingredients in treatments include delafloxacin, vancomycin, ceftaroline fosamil, oritavancin, tedizolid, daptomycin, tigecycline, linezolid, and others, with administration options including oral, parenteral, and topical routes. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, addressing various applications such as cellulitis, abscesses, surgical wounds, and traumatic wounds.

The acute bacterial skin and skin structure infections market research report is one of a series of new reports that provides acute bacterial skin and skin structure infections market statistics, including acute bacterial skin and skin structure infections industry global market size, regional shares, competitors with a acute bacterial skin and skin structure infections market share, detailed acute bacterial skin and skin structure infections market segments, market trends and opportunities, and any further data you may need to thrive in the acute bacterial skin and skin structure infections industry. This acute bacterial skin and skin structure infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 1-3 business days.